| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Lusianthridin targets the Src-STAT3 signaling pathway, leading to enhanced degradation of the oncoprotein c-Myc. Src is a non-receptor tyrosine kinase involved in cell proliferation, migration, and survival, while STAT3 is a transcription factor that regulates genes involved in cell growth and apoptosis. By inhibiting this pathway, Lusianthridin exerts anti-migratory and cytotoxic effects, making it a potential agent for cancer research.
|
|---|---|
| ln Vitro |
In both H460 and H292 cells, lenianthridin (0-100 μM) decreases cell viability at doses higher than 50 μM[1]. The CSC populations in the H460 and H292 cells of the CSC spheres are dramatically reduced by lasianthridin, with the size of the H460 CSC spheres significantly decreasing by roughly 10%, 63%, and 77% at day 3 at concentrations of 5, 10, and 20 μM, respectively[1].
In vitro, Lusianthridin shows appreciable cytotoxicity against human lung cancer cell lines. It exhibits anti-migratory properties at non-toxic concentrations. Lusianthridin enhances c-Myc degradation through the inhibition of Src-STAT3 signaling. These in vitro activities support its potential as an anticancer agent, particularly for studying the Src-STAT3-c-Myc axis in cancer progression and metastasis. |
| ln Vivo |
In vivo data for Lusianthridin is not extensively reported in publicly available sources. As a natural compound with anti-migratory and cytotoxic activities against lung cancer cells in vitro, Lusianthridin has potential applications in animal models of cancer, particularly for studying metastasis and tumor growth. However, specific published in vivo efficacy studies are not detailed in the current literature. Lusianthridin is primarily used as a research tool for studying cancer biology and natural product pharmacology.
|
| Enzyme Assay |
The in vitro cytotoxicity assay for Lusianthridin is conducted in human lung cancer cell lines. Cells are treated with varying concentrations of the compound, and cell viability is measured using standard assays such as MTT or CellTiter-Glo. Anti-migratory effects are assessed using wound healing or transwell migration assays at non-toxic concentrations. Src-STAT3 signaling inhibition and c-Myc degradation are confirmed by Western blotting for phosphorylated Src, phosphorylated STAT3, and c-Myc protein levels.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: The human non-small cell lung cancer cell lines, NCI-H460, and NCI-H292 cells[1]. 0-100 μM. Tested Concentrations: 0-100 μM. Incubation Duration: 24 h. Experimental Results: Caused a significant reduction in terms of cell viability at concentrations greater than 50 μM in both H460 and H292 cells. Cellular assays for Lusianthridin are conducted in human lung cancer cell lines. Cells are treated with varying concentrations of Lusianthridin for 24-72 hours. Cell viability and proliferation are measured using standard assays such as MTT or CellTiter-Glo. Cell migration is assessed using wound healing or Boyden chamber assays. Src-STAT3 pathway inhibition is evaluated by Western blotting for phosphorylated Src, phosphorylated STAT3, and c-Myc protein levels. Apoptosis may be assessed by flow cytometry. |
| Animal Protocol |
In vivo studies for Lusianthridin would typically involve xenograft mouse models of lung cancer or other malignancies. The compound would be administered via intraperitoneal or oral routes at doses determined by pharmacokinetic studies. Efficacy would be assessed by measuring tumor growth inhibition and metastasis. However, specific published in vivo protocols for Lusianthridin are not available in the current literature. The compound is currently used as a research tool for studying cancer biology.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Lusianthridin is not extensively reported in publicly available sources. The compound has a molecular weight of 242.27 g/mol and a molecular formula of C15H14O3. It has a CAS number of 87530-30-1 and is isolated from Dendrobium species. As a small molecule natural product, it is expected to have moderate bioavailability. Detailed PK parameters such as half-life and bioavailability are not available in the current literature for this research compound.
|
| Toxicity/Toxicokinetics |
Toxicity data for Lusianthridin is limited in publicly available sources. The compound exhibits anti-migratory properties at non-toxic concentrations, suggesting a favorable safety profile in vitro. As with all research compounds, Lusianthridin is intended for research use only and not for human therapeutic applications. Standard in vitro cytotoxicity assays and in vivo tolerability studies would be required for a complete toxicity assessment.
|
| References | |
| Additional Infomation |
7-Methoxy-9,10-dihydrophenanthrene-2,5-diol is a dihydrophenanthrene. It has been reported that 7-methoxy-9,10-dihydrophenanthrene-2,5-diol exists in yam, reeds, and other organisms with relevant data.
Lusianthridin is a dihydrophenanthrene compound isolated from Dendrobium venustum and Dendrobium nobile. It exhibits cytotoxicity against human lung cancer cell lines and has anti-migratory effects at non-toxic concentrations. Lusianthridin enhances c-Myc degradation through inhibition of Src-STAT3 signaling. It has a molecular formula of C15H14O3 and a molecular weight of 242.27 g/mol. Lusianthridin is a valuable research tool for studying cancer biology, metastasis, and the Src-STAT3-c-Myc signaling axis. |
| Molecular Formula |
C15H14O3
|
|---|---|
| Molecular Weight |
242.27
|
| Exact Mass |
242.094
|
| CAS # |
87530-30-1
|
| PubChem CID |
442702
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.872
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
18
|
| Complexity |
294
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
RDKDIPDDUFMMMT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H14O3/c1-18-12-7-10-3-2-9-6-11(16)4-5-13(9)15(10)14(17)8-12/h4-8,16-17H,2-3H2,1H3
|
| Chemical Name |
7-methoxy-9,10-dihydrophenanthrene-2,5-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1276 mL | 20.6381 mL | 41.2763 mL | |
| 5 mM | 0.8255 mL | 4.1276 mL | 8.2553 mL | |
| 10 mM | 0.4128 mL | 2.0638 mL | 4.1276 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
